A quick-read guide to the Trump administration’s MFN pricing policy and what it means for biopharma
GLOBAL BIOPHARMA DESK — The U.S. government has struck deals with 17 major drug companies, covering about 86% of the branded drug market, to lower U.S. prices to match the lowest price the company charges anywhere else in the world. This is “Most-Favored-Nation” (MFN) pricing — and it’s now one of the biggest forces reshaping drug prices in America.
How It Works, in Plain Terms
- The deal: Drugmakers agree to price certain drugs in the U.S. at the same low price they charge in other rich countries.
- The platform: A federal website, TrumpRx.gov (launched February 2026), routes patients to manufacturer sites offering these discounted cash prices.
- The leverage: Companies that sign get a 3-year exemption from new pharmaceutical import tariffs. Companies that don’t sign face those tariffs — a strong incentive to participate.
Unlike Medicare’s separate drug price negotiation program (which only affects what Medicare pays), MFN pricing is aimed at everyone — commercial insurance, Medicaid, and especially cash-paying patients.
Real Price Changes Already Happening
| Drug | Company | Old Price (monthly) | New MFN/Cash Price | Discount |
|---|---|---|---|---|
| Ozempic | Novo Nordisk | ~$1,028 | as low as $199 | ~81% |
| Wegovy (injectable) | Novo Nordisk | ~$1,349 | ~$199–245 | ~82% |
| Zepbound | Eli Lilly | ~$1,088 | as low as $299 | ~73% |
| Praluent | Regeneron | $537 | $225 | 58% |
| Farxiga | AstraZeneca | list price | up to 80% off | up to 80% |
| Insulin (NovoLog, Tresiba, etc.) | Novo Nordisk | varies | $35/month | — |
Note: these are direct-to-consumer/cash-pay prices under MFN agreements — not what every insured patient pays.
Why It’s Different From Other Pricing Pressure
We’ve covered three other types of U.S. drug pricing pressure this year — Lilly’s own voluntary discounting, Novartis’s patent-cliff generic erosion, and Medicare’s IRA negotiation program. MFN pricing is a fourth, and it’s the broadest:
| Pricing Pressure | Who Decides | What It Affects |
|---|---|---|
| Self-pay discounting (e.g., LillyDirect) | The company, voluntarily | One product/channel |
| Generic erosion (e.g., Entresto) | The market, once patent expires | One product |
| Medicare negotiation (IRA) | The government, by law | Medicare Part D only |
| MFN pricing | The government, via trade deals | Whole portfolio, all payers |
What to Watch
- It’s still voluntary, not law. The deals rely on the current administration keeping up tariff pressure — not yet locked in by Congress.
- List prices vs. cash prices. Some companies have kept raising official list prices even while offering these lower MFN cash prices — so the “discount” only applies to a specific channel, not the sticker price everywhere.
- New drugs are included too. Several companies agreed to apply MFN pricing to future launches, not just today’s bestsellers — meaning this will shape pricing strategy for new drugs going forward.
BioNextAI Market Insights View
MFN pricing is the broadest of the four pricing pressures now hitting U.S. biopharma — it touches whole portfolios, not single products, and uses trade policy instead of health policy as its enforcement tool. That makes it powerful, but also less permanent than it looks: it depends on continued White House pressure rather than a change in law. Companies planning multi-year pricing strategy should treat MFN commitments as a live, evolving factor — not a one-time deal to file away.
About Bionext AI Market Insights Data-driven intelligence on biopharma commercial strategy, market access, and competitive dynamics.
Sources: The White House (executive orders, fact sheets, CEA report); HHS/CMS statements; AMCP; GovFacts; industry reporting (FiercePharma, BioSpace, AJMC). Figures current as of publication; MFN agreement terms are evolving.
By
